Utah: Committee Unanimously Passes Medical Marijuana Research Bill
By Derrick Stanley
Utah’s House Health and Human Services committee unanimously passed House Bill 130, allowing research on medical marijuana without federal approval.
State Representative Brad Daw (R), the bill’s sponsor in the House, said, “This is the first step in what I think is the right policy direction for this state.”
The proposal specifically:
allows a person to possess cannabis, a cannabinoid product, and an expanded cannabinoid product and to distribute the cannabis, a cannabinoid product, or an expanded cannabinoid product to a patient pursuant to an institutional review board-approved study; and
allows a person conducting an institutional review board-approved study to import and distribute cannabis, a cannabinoid product, and an expanded cannabinoid product under certain circumstances.
Proponents of medical marijuana are frustrated with the decision, believing there is plenty of research to prove its medical use, and want the state to expand upon a law passed in 2014 that allows for the medical use of low-THC, high-CBD cannabis oil, but only for those with epilepsy to allow full-plant use (as well as THC), and to greatly expand the list of qualifying conditions.
Karen Buchi, a pediatrician who oversees a marijuana and opioid task force, told the committee that university researchers are currently studying marijuana under federally approved licenses, and that the legislation wouldn’t change how they operate in any way. This frustrates medical marijuana advocates even more, who consider the move to be ineffective.